Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
GSK Biologicals' Recombinant CMV gB Vaccine GSK1492903A · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Group A | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| GSK Biologicals' Recombinant CMV gB Vaccine GSK1492903A | BIOLOGICAL | Intramuscular injection, 3 doses |
Inclusion Criteria: * Subjects who the investigator believes that they can and will comply with the requirements of the protocol should be enrolled in the study. * Male between, and including, 18 and 40 years of age at the time of the first vaccination. * Written informed consent obtained from the ...
GSK Biologicals' Recombinant CMV gB Vaccine GSK1492903A is an investigational vaccine developed by GSK plc for cytomegalovirus infections. It is a recombinant vaccine candidate designed to prevent CMV infection. The vaccine has been studied in a Phase 1 clinical trial in CMV-seronegative healthy male adults.
GSK Biologicals' Recombinant CMV gB Vaccine GSK1492903A is being developed for the prevention of cytomegalovirus infections. CMV is a common virus that can cause serious complications in immunocompromised individuals and newborns. The vaccine is intended to induce immune responses against CMV in healthy adults.
GSK Biologicals' Recombinant CMV gB Vaccine GSK1492903A is being developed by GSK plc, a global pharmaceutical company. GSK plc is listed on the New York Stock Exchange under the ticker symbol GSK. The company's vaccines division, GSK Biologicals, is responsible for the development of this CMV vaccine candidate.
GSK Biologicals' Recombinant CMV gB Vaccine GSK1492903A is in Phase 1 clinical development. It has completed one Phase 1 trial. As an investigational vaccine, it has not been approved by the FDA or any regulatory agency for commercial use.
GSK Biologicals' Recombinant CMV gB Vaccine GSK1492903A has been evaluated in a Phase 1 clinical trial, NCT00435396, titled 'Study to Evaluate Safety and Immunogenicity of the GSK Bio CMV Vaccine in CMV-seronegative Healthy Male Adult Subjects.' The trial enrolled 40 participants in Belgium and is completed.